Scalper1 News
Big pharma Merck affirmed Tuesday that it’s going ahead with its $9.5 billion acquisition of biotech Cubist Pharmaceuticals even though Cubist’s lead drug looks to face generic competition sooner than expected. Merck (MRK) stock was down 4.5% in morning trading on the stock market today, while Cubist Pharmaceuticals (CBST) stock was off more than 3.5%. Merck announced the Cubist acquisition Monday morning, hours before a federal judge in Delaware Scalper1 News
Scalper1 News